Özde Melisa Celayir’s Post

Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives 🔬 #ClinicalOncology #Oncology #Cancer

Now published in the Springer Nature International Journal of Clinical Oncology: read about the safety and pharmacokinetics of a #PROTAC ER degrader in Japanese patients with advanced breast cancer. Read the paper here: https://bit.ly/3ZnstDR #clinicaltrials #BreastCancer

Discover the potential of Claudin 18.2 in precision medicine. From its physiological role in gastric epithelium to its emergence as a novel target for innovative cancer treatments, explore how this molecule is reshaping oncology research in our newest video! #CancerResearch #Claudin18 #Oncology

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials #Fortrea #TalentInfluencersLeaderboard #FortreaAlwaysOn

Anastomotic leak (AL) is one of the most serious complications following esophagectomy for esophageal cancer. A new multivariate meta-analysis examines the impact of AL on long-term survival, offering critical insights for surgical oncology practices. Discover the detailed findings in Annals of Surgical Oncology: https://ow.ly/F79p50UqOYs #FeaturedArticle

🚨 Big news 🚨 💊 Inavolisib is now approved for use in combination with palbociclib and fulvestrant in front line setting for endocrine-resistant HR+, HER2- disease with PIK3CA mutation. This approval further highlights the role of genomic testing 🧬 for treatment selection (prior to treatment initiation) in advanced breast cancer #bcsm #precisiononcology #biomarkers

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

Are you intrigued by the potential to predict neoadjuvant chemotherapy outcomes in breast cancer patients? I'm excited to share the groundbreaking #ARTIDIS innovation with you at #AACR2024. Let's explore the future of oncology together! #predictivebiomarkers5 (raw 43, poster 6)